OSA-Direct
Friday, 20 Oct 2017

U.S. Senator Tom Carper visits Adesis New Castle facility to discuss innovation and job growth

Senator aiming to find out how our Delaware companies are doing and what government can do to create a nurturing environment for job creation

25 Aug 2017 | Editor

Adesis, Inc has announced that U.S. Senator Tom Carper recently visited its New Castle facility. Senator Carper toured Adesis' laboratories to observe first-hand the company's research and development in materials and pharmaceutical sciences, and met with senior management to discuss growth opportunities that are expected to further boost research and innovation in Delaware.

Adesis - founded in 1991 in Newport, Delaware - recently purchased its New Castle, Delaware building in May 2017 to expand its custom organic synthesis, research & development, and speciality manufacturing capabilities.

The New Castle, DE facility is a 47,500-square-foot building in the Southgate Industrial Center, of which Adesis had previously leased about 25,100 square feet.

Adesis - Senator Tom Carper touring Adesis’ state-of-the-art labs with Dr. Andrew Cottone, President of Adesis

Figure: Adesis - Senator Tom Carper touring Adesis’ state-of-the-art labs with Dr. Andrew Cottone, President of Adesis

"When the Senate is out of session, I tour Delaware visiting with businesses like Adesis for what I like to call 'Customer Calls', where I can find out how our local companies are doing and what we can do in government to create a nurturing environment for job creation."

"I'm so pleased that Adesis has chosen Delaware, with its first-class workforce, to expand its operations."

Senator Tom Carper


"We are very pleased to have the opportunity to host Senator Tom Carper at our facility and showcase the latest developments at Adesis."

"As a leading organic synthesis CRO (contract research organization), we are broadening our presence in Delaware and appreciate Senator Carper’s long-standing support of businesses and new career opportunities. The recent purchase of our building will allow us to expand our critical mass, increase our headcount, and further grow our custom molecular synthesis, research, development, and specialty manufacturing business across the pharmaceutical, chemical, biomaterials, and catalysts industries."

Andrew Cottone, President of Adesis, Inc.

www.udcoled.com    www.adesisinc.com   


About Adesis

As a wholly-owned subsidiary of Universal Display Corporation, Adesis, Inc. is a contract research organization (CRO) supporting the pharma, biotech, catalysis and a number of other industries. The CRO specializes in organic and organometallic synthesis, in milligrams to multi-kilogram quantities.

Adesis has a business model of providing clients with organic chemistry services in three areas: early stage research, scale up and development, and specialty manufacturing. With over 20 years of success and over 50 chemists with extensive industry and professional experience, Adesis supports companies in various industries with small molecule organic chemistry expertise. Adesis provides a range of services that can supplement research and development efforts. It can also act as a specialty manufacturer to reinforce supply chains.

Source: Adesis


login
cintelliq logo